A sejtfelszíni antigének heterogenitása B-sejtes krónikus lymphoid leukaemiában.

Translated title of the contribution: Heterogeneity of surface antigens in chronic B-cell lymphoid leukemia

K. Pálóczi, M. Benczúr, R. Mihalik, V. Solti, Z. Hollán

Research output: Contribution to journalArticle

Abstract

Clinical and immunological studies of fifty patients with CLL have been performed. No correlation was found either between the clinical stage or clinical course of the disease and the distribution of cell surface makers characteristic of CLL (CD19, CD20, CD21, HLA-DR, sIg). Therapy did not influence the distribution of B lymphocyte subpopulations. On the other hand we recognized differences when examining the B-cell specific features. The CD21 antigen was present in significantly lower proportion when compared to all other B-cell markers. This suggests the presence of immature B-cell population. Correlation studies showed a strong correlation between the presence of the CD5 antigen and the antigens CD19, CD20, HLA-DR and sIg, while a similar correlation could not be proved between the CD5 antigen and CD21 marker. Thus the application of the CD5 antibody together with any of the B-cell markers seems to be sufficient for the diagnostics of CLL with the exception of the CD21 antibody that marks only a small proportion of the B-cell population in CLL, so it can be used for purposes of clinical diagnostics.

Original languageHungarian
Pages (from-to)7-8, 11
JournalOrvosi Hetilap
Volume132
Issue number1
Publication statusPublished - Jan 6 1991

Fingerprint

Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Surface Antigens
B-Lymphocytes
CD5 Antigens
HLA-DR Antigens
CD19 Antigens
CD20 Antigens
Complement 3d Receptors
B-Lymphoid Precursor Cells
Antibodies
Lymphocyte Subsets
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A sejtfelszíni antigének heterogenitása B-sejtes krónikus lymphoid leukaemiában. / Pálóczi, K.; Benczúr, M.; Mihalik, R.; Solti, V.; Hollán, Z.

In: Orvosi Hetilap, Vol. 132, No. 1, 06.01.1991, p. 7-8, 11.

Research output: Contribution to journalArticle

Pálóczi, K. ; Benczúr, M. ; Mihalik, R. ; Solti, V. ; Hollán, Z. / A sejtfelszíni antigének heterogenitása B-sejtes krónikus lymphoid leukaemiában. In: Orvosi Hetilap. 1991 ; Vol. 132, No. 1. pp. 7-8, 11.
@article{1a223a8b805248ce9ed89ed858cb4e9d,
title = "A sejtfelsz{\'i}ni antig{\'e}nek heterogenit{\'a}sa B-sejtes kr{\'o}nikus lymphoid leukaemi{\'a}ban.",
abstract = "Clinical and immunological studies of fifty patients with CLL have been performed. No correlation was found either between the clinical stage or clinical course of the disease and the distribution of cell surface makers characteristic of CLL (CD19, CD20, CD21, HLA-DR, sIg). Therapy did not influence the distribution of B lymphocyte subpopulations. On the other hand we recognized differences when examining the B-cell specific features. The CD21 antigen was present in significantly lower proportion when compared to all other B-cell markers. This suggests the presence of immature B-cell population. Correlation studies showed a strong correlation between the presence of the CD5 antigen and the antigens CD19, CD20, HLA-DR and sIg, while a similar correlation could not be proved between the CD5 antigen and CD21 marker. Thus the application of the CD5 antibody together with any of the B-cell markers seems to be sufficient for the diagnostics of CLL with the exception of the CD21 antibody that marks only a small proportion of the B-cell population in CLL, so it can be used for purposes of clinical diagnostics.",
author = "K. P{\'a}l{\'o}czi and M. Bencz{\'u}r and R. Mihalik and V. Solti and Z. Holl{\'a}n",
year = "1991",
month = "1",
day = "6",
language = "Hungarian",
volume = "132",
pages = "7--8, 11",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "1",

}

TY - JOUR

T1 - A sejtfelszíni antigének heterogenitása B-sejtes krónikus lymphoid leukaemiában.

AU - Pálóczi, K.

AU - Benczúr, M.

AU - Mihalik, R.

AU - Solti, V.

AU - Hollán, Z.

PY - 1991/1/6

Y1 - 1991/1/6

N2 - Clinical and immunological studies of fifty patients with CLL have been performed. No correlation was found either between the clinical stage or clinical course of the disease and the distribution of cell surface makers characteristic of CLL (CD19, CD20, CD21, HLA-DR, sIg). Therapy did not influence the distribution of B lymphocyte subpopulations. On the other hand we recognized differences when examining the B-cell specific features. The CD21 antigen was present in significantly lower proportion when compared to all other B-cell markers. This suggests the presence of immature B-cell population. Correlation studies showed a strong correlation between the presence of the CD5 antigen and the antigens CD19, CD20, HLA-DR and sIg, while a similar correlation could not be proved between the CD5 antigen and CD21 marker. Thus the application of the CD5 antibody together with any of the B-cell markers seems to be sufficient for the diagnostics of CLL with the exception of the CD21 antibody that marks only a small proportion of the B-cell population in CLL, so it can be used for purposes of clinical diagnostics.

AB - Clinical and immunological studies of fifty patients with CLL have been performed. No correlation was found either between the clinical stage or clinical course of the disease and the distribution of cell surface makers characteristic of CLL (CD19, CD20, CD21, HLA-DR, sIg). Therapy did not influence the distribution of B lymphocyte subpopulations. On the other hand we recognized differences when examining the B-cell specific features. The CD21 antigen was present in significantly lower proportion when compared to all other B-cell markers. This suggests the presence of immature B-cell population. Correlation studies showed a strong correlation between the presence of the CD5 antigen and the antigens CD19, CD20, HLA-DR and sIg, while a similar correlation could not be proved between the CD5 antigen and CD21 marker. Thus the application of the CD5 antibody together with any of the B-cell markers seems to be sufficient for the diagnostics of CLL with the exception of the CD21 antibody that marks only a small proportion of the B-cell population in CLL, so it can be used for purposes of clinical diagnostics.

UR - http://www.scopus.com/inward/record.url?scp=0026417584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026417584&partnerID=8YFLogxK

M3 - Article

VL - 132

SP - 7-8, 11

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 1

ER -